On Mar. 30, Mind Medicine (MindMed) Inc. filed a preliminary short form base shelf prospectus with securities regulators in each of the provinces and territories of Canada and a corresponding registration statement on Form F‐10 with the U.S. Securities and Exchange Commission in accordance with the multijurisdictional disclosure system established between Canada and the U.S.
The base shelf prospectus and registration statement, when made final or effective, will permit MindMed to offer and sell subordinate voting shares, multiple voting shares, warrants, subscription receipts, units or any combination thereof in various offerings having an aggregate value of up to $500 million during the 25-month period that the base shelf prospectus remains effective. This is the first base shelf prospectus filed by a psychedelics company.
Cassels Brock & Blackwell LLP acted as Canadian counsel for MindMed with a deal team composed of
David Singh (securities).
Troutman Pepper Hamilton Sanders LLP acted as U.S. counsel for MindMed with a deal team composed of